一财直击第十一批国家药品集采开标，有哪些新变化？

Core Points - The 11th batch of national organized drug procurement was held in Shanghai on October 27, involving 55 drug varieties across various therapeutic areas including anti-infection, anti-tumor, asthma, diabetes, cardiovascular, and neurological drugs [2][9] - The procurement process introduced new mechanisms such as "revival for non-selected" opportunities to encourage more companies to participate at suitable prices, extending the bidding time compared to previous batches [9][10] - The procurement emphasizes principles of maintaining clinical stability, ensuring quality, preventing excessive competition, and avoiding collusion among related companies [10][11] Group 1: Procurement Details - The procurement involved 55 drug varieties and was conducted with a focus on transparency and public engagement, including online explanations of selection rules for medical institutions [11] - Since 2018, 10 batches of drug procurement have been conducted, covering 435 drug types and nearly 800 pharmaceutical companies, with over 2000 representative products involved [9][10] - The bidding process was structured to allow medical institutions to report quantities either by generic name or specific brand, with 77% of the 46,000 institutions reporting by brand [10] Group 2: Competitive Landscape - The average number of companies bidding per drug variety was 14, indicating a competitive environment, although some drugs had significantly more bidders, leading to intense competition [11][13] - The National Medical Insurance Administration issued a warning in August for companies to conduct cost-benefit analyses and maintain rational pricing strategies in light of high competition [13]